ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Experimental evaluation of Nilotinib and Paclitaxel co-delivered via albumin nanoparticles as a therapeutic strategy for lung squamous cell carcinoma.Clinical and experimental medicine · 2026Article
- Beyond a Metabolite: Lactylation as a Pivotal Regulator of Colorectal Cancer Pathogenesis and Treatment Resistance.Journal of biochemical and molecular toxicology · 2026Review
- Porphyrin oriented bimetallic sonodynamic MOF for enhanced ferroptosis and cGAS-STING pathway mediated antitumor immunotherapy.Journal of nanobiotechnology · 2026Article
- Compound 17 Inhibits Lung Cancer Progression via Inducing Cellular Apoptosis and Blocking TNF Signaling Pathway Activation.International journal of molecular sciences · 2026Article
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
- FOXC1 drives lung cancer metastasis and functions as a target for AI-enabled anti-metastatic drug discovery.Frontiers in pharmacology · 2026Article
- Inhalable Herbal Nano-Liposomes Co-Delivering Astragaloside IV and Polyphyllin VII Reprogram Immunosuppressive Microenvironment To Overcome Anti-PD-1 Resistance in NSCLC.Biological procedures online · 2025Article
- Recent Advancements in Lung Cancer Metastasis Prevention Based on Nanostrategies.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metastasis is the leading cause of death in patients with lung cancer. Multidisciplinary comprehensive treatments (MDT), including surgery, chemotherapy, radiotherapy, gene-targeted therapy, immunotherapy, antibody-drug conjugate (ADC), natural products, etc., have been currently used for lung cancer metastasis. The MDT model has shown promising efficacy against lung cancer metastasis in clinical practice. However, these therapies have some limitations, such as unusual toxic side effects, drug resistance, limited indications, and high costs. Therefore, emerging technological platforms are imperative to overcome these bottlenecks. Nanomedicine can be used to prepare efficient drug delivery systems owing to its good biocompatibility, high targeting, responsive release, and multidrug codelivery and plays an important role in the synergistic antimetastasis of lung cancer because of the optical, acoustic, electrical, thermal, and magnetic functions. This comprehensive review analyses the limitations of the MDT model, briefly outlines the advantages of nanotechnology, introduces the promising nanodrug delivery systems, summarizes the emerging nanostrategies against lung cancer metastasis based on the invasion-metastasis cascade process, and provides a summary of the prospects and challenges for the clinical translation of nanomedicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.